Biochemical and Biophysical Research Communications
In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9
Introduction
Cervical cancer is the second most common type of malignancy among women worldwide and a leading cause of mortality among females in developing countries. It affects nearly half a million women each year, claiming a quarter of a million lives [1], [2]. According to several epidemiological and biological studies, human papilloma viruses (HPV) infection is the dominant etiological event in CC development [3], HPV DNA can be detected in more than 95% of cervical cancer and intraepithelial neoplasia biopsies [4], demonstrating the strong association of this cancer with HPV infection.
Human papillomaviruses (HPVs) are small DNA viruses with a genome of approximately 8 kb. A small subgroup, types 16, 18, 31, 33, and 45, has been designated high-risk HPVs and found to be associated with more that 90% of cervical cancers [5], of which HPV16 accounts for approximately 50% [6]. The oncogenic function of HPVs has been primarily attributed to E6 and E7, which are essential for malignant transformation and pivotal for maintenance of the malignant phenotype of cervical cancer [7], [8]. They are selectively expressed in HPV-related cancer cells to inactively tumor suppressor proteins such as P53 and pRb, leading to cell cycle disorder, telomerase activation, and cell immortalization. E6 is able to induce the degradation of p53, thereby inhibiting p53-dependent signaling, and contributing to tumorigenesis [9], [10]. In the case of E7, deregulation of the host cell cycle seems to be a major function of the oncoprotein. It is associated with the retinoblastoma family of proteins: pRb [11], [12], p107, and p130 [13], [14]), as well as cyclin-dependent kinase inhibitors of p21 [15], [16] and p27 [17], and prevents G1 arrest in response to a variety of antiproliferative signals, such as growth factor withdrawal, loss of cell adhesion, and DNA damage [18]. Because of the strong relationship between the expression of this group of HPV oncogenes and cervical cancer carcinogenesis, development of novel approaches directed against these oncogenes may provide a novel block therapy for cervical cancer.
Clustered regularly interspaced short palindromic repeats CRISPR-associated (Cas9) is a recently discovered, site-specific genome editing system that is part of the CRISPR–Cas bacterial acquired immune system, which cleaves foreign DNA [19], [20]. And the CRISPR/Cas9 system requires the design of only a single guide sequence that matches the DNA targeted for cleavage. Since the first report of the use of CRISPR/Cas9 for genome editing in human cells in 2013 [21], [22], [23], this technology has been used in vivo in human cells and other organisms. Molecular-targeting therapy with Cas9 is expected to prevent the development for disease caused by foreign genes, such as human immunodeficiency virus (HIV) infection, by inhibiting expression of genes [24]. And Fujii et al. [25] indicate the availability of CRISPR/Cas9 system for the large-scale deletion and imply the system is highly efficient for genome modification. Therefore, strategies for achieving specific and selective CRISPR/Cas9 to abrogate E6 and E7 function may be a rational therapeutic approach for treating HPV-positive cervical cancers.
In the hope of applying CRISPR/Cas9 as therapy for HPV-related cancer, in this study, we have designed a CRISPR/Cas9 system that targets E6 and E7. We have shown that a CRISPR/Cas9 system can effectively, specifically and stable suppress HPV-16 E6 and E7 expression in vitro and in vivo, and also demonstrated that the cervical tumor growth could be inhibited for mouse by CRISPR/Cas9 treatment.
Section snippets
gRNA expression plasmids
gRNA expression plasmids were constructed according to manufacturer’s protocol [26], [27]. Briefly, to prepare a 100-bp dsDNA insert fragment containing the target sequence (20 bp) and a protospacer-adjacent motif (PAM) sequence, we used a set of oligonucleotides and generated the fragment using T4 PNK (NEB; Ipswich, MA, USA). The dsDNA fragment was purified and inserted into the BbsI site of a gRNA cloning vector with T4 DNA ligase (NEB). Detailed BLAST searching of human and murine genomes was
Inhibition of E6 and E7 expression by CRISPR/Cas9
SiHa cells were used to examine the effects of E6 or E7 gene knockdown by CRISPR/Cas9. A total of ten gRNA were designed and their effects on E6 and E7 gene expression were determined by RT-PCR analysis after transfection of each specific CRISPR/Cas9 into cells. As shown in Fig 1, levels E6 and E7 expression in SiHa cells transduced by the CRISPR+Cas9+promoter-1 were reduced by 94% and 91%, compared to the blank, at 48 h. The CRISPR+Cas9+E6-4 showed effective knockdown of HPV16-E6 gene
Discussion
Cervical cancer is the second most common cancer in women worldwide though well organized screening has been expanded, and the majority of cases are caused by high-risk types of human papillomavirus, which possess the E6 and E7 oncogenes. Studies have demonstrated that the expression of these oncogenes is indispensable for tumor development and maintenance of malignant phenotypes [31]. Clinical data show that the prognosis of cervical cancer patients remains unoptimistic up to data, with a
Conflict of interest
The authors declare no conflicts of interest.
Acknowledgment
We thank Sakamoto H, (Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA) for the excellent technical assistance.
References (38)
- et al.
Requirement of E7 oncoprotein for viability of HeLa cells
Microbes Infect.
(2006) - et al.
The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53
Cell
(1993) - et al.
In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by E6 siRNA
Mol. Ther.
(2003) - et al.
Carcinoma of the cervix uteri. FIGO 26th Annual Report on the results of treatment in Gynecological cancer
Gynaecol. Obstet.
(2006) - et al.
One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering
Cell
(2013) Molecular biology of human papillomavirus infection and cervical cancer
Clin. Sci.
(2006)A public health approach to cervical cancer control: considerations of screening and vaccination strategies
Int. J. Gynecol. Obstet.
(2006)- et al.
Glutathione S-transferase polymorphism interactions with smoking status and HPV infection in cervical cancer risk: an evidence-based meta-analysis
PLOS ONE
(2013) - et al.
Mechanisms of human papillomavirus induced oncogenesis
J. Virol.
(2004) Heterogeneity of the human papillomavirus group
J. Virol.
(1989)
Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group
J. Natl. Cancer Inst.
Papillomaviruses and cancer: from basic studies to clinical application
Nat. Rev. Cancer
Association of human papillomavirus types 16 and 18 E6 proteins with p53
Science
Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product
EMBO J.
The human papilloma virus 16 E7 oncoprotein is able to bind to the retinoblastoma gene product
Science
Homologous sequences in adenovirus E1A and human papillomavirus E7 proteins mediate interaction with the same set of cellular proteins
J. Virol.
Human papillomavirus type 16 E7 associates with a histone H1 kinase and with p107 through sequences necessary for transformation
J. Virol.
Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein
Genes Dev.
The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21-mediated inhibition of cdk2
Genes Dev.
Cited by (181)
Gene editing for stem cells by CRISPR-Cas9
2023, Stem Cell Laboratory Techniques: A Guide for Researchers and StudentsCRISPR/Cas9 genetic screens in hepatocellular carcinoma gene discovery
2023, Current Research in BiotechnologyThe power and the promise of CRISPR/Cas9 genome editing for clinical application with gene therapy
2022, Journal of Advanced ResearchCitation Excerpt :The in vivo experiment also evidenced the accessibility of cervical carcinoma treatment via targeting HPV E6 and E7 by Cas9. After introducing indels in E6 and E7, the dramatical inhibition of tumorigenesis and tumor growth was observed[128], and the treatment combining with cis-diamine-dichloro platinum II (CDDP)[129]. Moreover, hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are also risky, causing almost 80% of hepatocellular carcinoma (HCC) in the world.
Cervical cancer therapies: Current challenges and future perspectives
2022, Tumour Virus Research
- 1
These authors contribute equally to this work.